Stoke, Biogen report four-year zorevunersen data showing sustained seizure control

Stoke Therapeutics and Biogen will present four-year results from Phase 1/2a open-label extension studies of zorevunersen for Dravet syndrome at the 16th European Epilepsy Congress in Athens, with data showing sustained cognitive and behavioral improvements, durable seizure reductions, and a generally well-tolerated safety profile. New exploratory analyses will examine effects on the most severe seizure types and quality of life as the program advances toward late-stage development. The companies note that more than 930 doses have been administered and that the Phase 1/2a data underpin the potential disease-modifying profile of zorevunersen, which is designed to boost functional NaV1.1 protein by targeting the SCN1A gene. Separately, Stoke plans to present at the Cantor Global Healthcare Conference on September 9, 2026, highlighting ongoing clinical activity and program milestones, alongside a live webcast of the event. The epilepsy field’s broader activity is underscored by GRIN Therapeutics’ participation in the European Epilepsy Congress, signaling continued collaboration and visibility among researchers, clinicians, and industry in this space. Overall, the combined updates reinforce zorevunersen’s potential as a first-in-class treatment for Dravet syndrome while signaling ongoing momentum in the anti-sense oligonucleotide approach and related collaborations.